Viatris income statement

In fiscal 2025, Viatris reported revenue of $14.30bn, down 3.0% on the year before, operating income of −$2.66bn (a -18.6% margin) and net income of −$3.51bn, or −$3.00 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Viatris: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	11.4	11.5	11.9	17.9	16.3	15.4	14.7	14.3	14.7
Cost of revenue	7.4	7.6	8.1	12.3	9.8	9.0	9.1	9.3	9.6
Gross profit	4.0	3.9	3.8	5.6	6.5	6.4	5.6	5.0	5.1
Research and development	0.7	0.6	0.6	0.8	0.7	0.8	0.8	1.0	1.0
Selling, general and administrative	2.4	2.6	3.3	4.5	4.2	4.1	4.1	3.8	4.0
Operating income	0.9	0.7	−0.2	−0.0	1.6	0.8	0.0	−2.7	−0.1
Interest expense	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.5	0.5
Income before tax	0.3	0.2	−0.7	−0.7	2.8	0.2	−0.6	−3.7	−0.7
Income tax	−0.1	0.1	−0.1	0.6	0.7	0.1	0.0	−0.2	−0.3
Net income	0.4	0.0	−0.7	−1.3	2.1	0.1	−0.6	−3.5	−0.4
Diluted EPS	$0.34	$0.01	−$0.56	−$1.05	$1.71	$0.05	−$0.53	−$3.00	—
Diluted shares (average)	1,033m	1,033m	1,202m	1,209m	1,217m	1,207m	—	—	—
EBITDA	3.0	2.7	2.0	4.5	4.6	3.5	2.9	0.1	2.7

US$ millions unless shown otherwise. Fiscal quarters.

Viatris: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	3,751	3,528	3,254	3,582	3,760	3,704	3,517	3,757
Cost of revenue	2,292	2,313	2,093	2,249	2,388	2,556	2,360	2,300
Gross profit	1,459	1,215	1,161	1,333	1,372	1,148	1,157	1,457
Research and development	198	207	222	219	250	275	249	248
Selling, general and administrative	1,003	1,047	948	929	887	1,031	929	1,135
Operating income	226	−180	−2,882	233	179	−193	−80	6
Interest expense	146	120	116	117	120	120	120	121
Income before tax	91	−527	−3,097	−217	−8	−343	−247	−64
Income tax	−4	−10	−55	−213	120	−3	−424	55
Net income	95	−517	−3,042	−5	−128	−340	176	−119
Diluted EPS	$0.08	−$0.43	−$2.55	$0.00	−$0.11	−$0.30	$0.15	−$0.10
EBITDA	896	566	−2,218	911	867	574	596	679

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: HLN vs VTRS UPC vs VTRS BHC vs VTRS VTRS vs ZTS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Viatris's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viatris.